Literature DB >> 20626735

Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging.

L Marciani1, J Wright, S Foley, C L Hoad, J J Totman, D Bush, C Hartley, A Armstrong, P Manby, E Blackshaw, A C Perkins, P A Gowland, R C Spiller.   

Abstract

BACKGROUND: 5-HT(3) antagonists have been shown to be effective in relieving the symptoms of irritable bowel syndrome with diarrhoea (IBS-D). Using a recently validated magnetic resonance imaging (MRI) method, we have demonstrated reduced fasting small bowel water content (SBWC) in IBS-D associated with accelerated small bowel transit. We hypothesized that slowing of transit with ondansetron would lead to an increase in SBWC by inhibiting fasting motility. AIM: To assess the effects of ondansetron compared with placebo in healthy volunteers on SBWC and motility in two different groups of subjects, one studied using MRI and another using manometry.
METHODS: Healthy volunteers were given either a placebo or ondansetron on the day prior to and on the study day. Sixteen volunteers underwent baseline fasting and postprandial MRI scans for 270 min. In a second study, a separate group of n = 18 volunteers were intubated and overnight migrating motor complex (MMC) recorded. Baseline MRI scans were carried out after the tube was removed.
RESULTS: Fasting SBWC was markedly increased by ondansetron (P < 0.0007). Ondansetron reduced the overall antroduodenal Motility Index (P < 0.04). The subjects who were intubated had significantly lower fasting SBWC (P < 0.0002) compared with the group of subjects who were not intubated.
CONCLUSIONS: The 5-HT(3) receptor antagonism increased fasting small bowel water. This was associated with reduced fasting antroduodenal Motility Index which may explain the clinical benefit of such drugs. 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626735     DOI: 10.1111/j.1365-2036.2010.04395.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

Review 1.  Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.

Authors:  Edoardo Savarino; Fabiana Zingone; Brigida Barberio; Giovanni Marasco; Filiz Akyuz; Hale Akpinar; Oana Barboi; Giorgia Bodini; Serhat Bor; Giuseppe Chiarioni; Gheorghe Cristian; Maura Corsetti; Antonio Di Sabatino; Anca Mirela Dimitriu; Vasile Drug; Dan L Dumitrascu; Alexander C Ford; Goran Hauser; Radislav Nakov; Nisha Patel; Daniel Pohl; Cătălin Sfarti; Jordi Serra; Magnus Simrén; Alina Suciu; Jan Tack; Murat Toruner; Julian Walters; Cesare Cremon; Giovanni Barbara
Journal:  United European Gastroenterol J       Date:  2022-06-13       Impact factor: 6.866

2.  Stimulation of colonic motility by oral PEG electrolyte bowel preparation assessed by MRI: comparison of split vs single dose.

Authors:  L Marciani; K C Garsed; C L Hoad; A Fields; I Fordham; S E Pritchard; E Placidi; K Murray; G Chaddock; C Costigan; C Lam; J Jalanka-Tuovinen; W M De Vos; P A Gowland; R C Spiller
Journal:  Neurogastroenterol Motil       Date:  2014-07-24       Impact factor: 3.598

Review 3.  Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment.

Authors:  Robin Spiller
Journal:  F1000Res       Date:  2016-04-29

4.  Effects of Bolus and Continuous Nasogastric Feeding on Gastric Emptying, Small Bowel Water Content, Superior Mesenteric Artery Blood Flow, and Plasma Hormone Concentrations in Healthy Adults: A Randomized Crossover Study.

Authors:  Abeed H Chowdhury; Kathryn Murray; Caroline L Hoad; Carolyn Costigan; Luca Marciani; Ian A Macdonald; Timothy E Bowling; Dileep N Lobo
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

Review 5.  Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Yongping Zheng; Ting Yu; Yurong Tang; Wenjie Xiong; Xiaoxue Shen; Ling Jiang; Lin Lin
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

6.  A pilot study of visceral fat and its association with adipokines, stool calprotectin and symptoms in patients with diverticulosis.

Authors:  Kathryn A Murray; Caroline L Hoad; Jill Garratt; Mehri Kaviani; Luca Marciani; Jan K Smith; Britta Siegmund; Penny A Gowland; David J Humes; Robin C Spiller
Journal:  PLoS One       Date:  2019-05-08       Impact factor: 3.240

Review 7.  Ethnic differences in genetic polymorphism associated with irritable bowel syndrome.

Authors:  Qi-Yun Xiao; Xiu-Cai Fang; Xiao-Qing Li; Gui-Jun Fei
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

8.  Increased fasting small-bowel water content in untreated coeliac disease and scleroderma as assessed by magnetic resonance imaging.

Authors:  Ching Lam; David S Sanders; Peter Lanyon; Klara Garsed; Stephen Foley; Susan Pritchard; Luca Marciani; Caroline L Hoad; Carolyn Costigan; Penny Gowland; Robin Spiller
Journal:  United European Gastroenterol J       Date:  2019-06-21       Impact factor: 4.623

9.  Colonic response to laxative ingestion as assessed by MRI differs in constipated irritable bowel syndrome compared to functional constipation.

Authors:  C Lam; G Chaddock; L Marciani; C Costigan; J Paul; E Cox; C Hoad; A Menys; S Pritchard; K Garsed; S Taylor; D Atkinson; P Gowland; R Spiller
Journal:  Neurogastroenterol Motil       Date:  2016-02-12       Impact factor: 3.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.